Combination Therapy For Prostate Cancer
AssigneeJanssen Pharmaceutica NV
InventorsLinda Anne Snyder, Margaret K. Yu
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.
Claims35
A method for treating a prostate cancer comprising administering to a patient in need thereof a therapeutically effective amount of niraparib, a therapeutically effective amount of abiraterone acetate, and a therapeutically effective amount of prednisone.
A pharmaceutical composition comprising niraparib, abiraterone acetate, and prednisone in a total amount that is in a single oral dosage form therapeutically effective for the treatment of prostate cancer in a human patient.
A pharmaceutical composition comprising niraparib, abiraterone acetate, and prednisone in a total amount that is in multiple oral dosage forms therapeutically effective for the treatment of prostate cancer in a human patient.
Dependencies are inferred from the claim text.